Sign In
Buy NVS
$153.38
+4.45 (+2.99%)
At Close: Jun 23, 2026
Novartis CEO: Broadly Positive About Business Momentum
05:40am, Tuesday, 23'rd Apr 2024
Novartis CEO Vas Narasimhan said the company saw a very good performance across both established medicines and recent drug launches. "While there was a small contribution from generics getting pushed
Novartis shares jump as drugmaker boosts outlook
03:48am, Tuesday, 23'rd Apr 2024
Novartis shares rallied on Tuesday as the Swiss drugmaker raised its outlook for the year after seeing strong demand for heart and psoriasis drugs.
Shares of Novartis climb 4.8% on raised guidance, better-than-expected results
03:35am, Tuesday, 23'rd Apr 2024
Shares of Swiss drugmaker Novartis climbed 4.8% in early deals Tuesday after it raised its full-year guidance following better-than-expected first-quarter results.
Novartis Ups Guidance on Profit, Sales Growth
01:31am, Tuesday, 23'rd Apr 2024
Novartis lifted its full-year guidance after first-quarter profit and sales rose and beat consensus expectations, boosted by strong sales of key drugs.
Novartis lifts FY guidance after Q1 results beat expectations
01:09am, Tuesday, 23'rd Apr 2024
Swiss drugmaker Novartis on Tuesday raised its full-year guidance after reporting better-than-expected first-quarter results.
Novartis (NVS) to Report Q1 Earnings: What to Expect?
11:11am, Friday, 19'th Apr 2024
Novartis (NVS) key drugs Entresto, Kisqali and Pluvicto are likely to have fueled its top and bottom-line numbers in the first quarter.
Exploring Analyst Estimates for Novartis (NVS) Q1 Earnings, Beyond Revenue and EPS
10:21am, Thursday, 18'th Apr 2024
Evaluate the expected performance of Novartis (NVS) for the quarter ended March 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics fo
2 High-Yield Dividend Stocks to Buy and Hold for 10 Years
09:30am, Wednesday, 17'th Apr 2024
Bristol Myers Squibb is turning on its innovative machine to get through recent patent cliffs. Novartis recently became a thinner company that is laser-focused on developing new medicines.
Novartis (NVS) Presents Positive Data on Rare Kidney Disease Drug
10:11am, Tuesday, 16'th Apr 2024
Novartis (NVS) announces encouraging data on Fabhalta from a phase III study for the treatment for the treatment of immunoglobulin A nephropathy, a heterogeneous, progressive, rare kidney disease.
Novartis (NVS) Inks Deal for ARVN's Prostate Cancer Candidate
02:56pm, Friday, 12'th Apr 2024
Novartis (NVS) enters into a license deal with Arvinas, Inc. (ARVN) for the worldwide development and commercialization of cancer candidate ARV-766. Shares of ARVN rise on the news.
Arvinas inks over $1.0 billion deal with Novartis
11:31am, Thursday, 11'th Apr 2024
Arvinas Inc (NASDAQ: ARVN) is in the green at writing after announcing a deal worth over $1.0 billion with Novartis (SWX: NOVN). Details of Arvinas – Novartis agreement Novartis will pay $150 millio
Novartis (NVS) to Undertake Job Cuts in Development Department
10:46am, Thursday, 11'th Apr 2024
Novartis (NVS) is set to cut jobs by 680 in its development organization to reshape workforce.
Novartis begins tender offer for MorphoSys
04:57am, Thursday, 11'th Apr 2024
Novartis said on Thursday that its tender offer for MorphoSys has begun, with an offer price of 68 euros ($73.08) per share in cash, corresponding to a premium of 142% on the volume-weighted average p
Novartis Layoffs 2024: What to Know About the Latest NVS Job Cuts
10:12am, Wednesday, 10'th Apr 2024
Novartis (NYSE: NVS ) layoffs are in the news Wednesday after the healthcare company announced plans to cut jobs in the U.S. and Switzerland. Starting with its U.S. jobs, the company intends to reduce
Meet Europe's Mag 18. Novo Nordisk Stock, ASML, and Others Can Rival the Mag Seven.
11:42am, Tuesday, 09'th Apr 2024
The Mag Seven stocks have powered gains in the U.S. market. Now, the hunt is on for an equivalent group of outperformers elsewhere.
